Importance of ancillary supplies for subcutaneous immunoglobulin infusion: Management of the local infusion site

Journal of Infusion Nursing

Volumn 36, Issue 6, 2013, Pages 384-390

  Duff, Carla ^a,d   Ochoa, Diana ^b   Riley, Patty ^c   Murphy, Elyse ^c   Zampelli, Annette ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Dallas Allergy and Immunology   (United States)

^c CSL Behring LLC   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Infusion; Intravenous immunoglobulin; Needles; Primary immunodeficiency; Subcutaneous immunoglobulin; Tape; Tolerability; Tubing

Indexed keywords

IMMUNOGLOBULIN; POLYURETHAN;

ADULT; ALGORITHM; ARTICLE; CHILD; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HOSPITAL EQUIPMENT; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFUSION RELATED REACTION; INJECTION SITE BURNING; INJECTION SITE EDEMA; INJECTION SITE SWELLING; MALE; NEEDLE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WALKING DIFFICULTY; X LINKED AGAMMAGLOBULINEMIA; YOUNG ADULT;

ADULT; ALGORITHMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULINS; INFUSIONS, SUBCUTANEOUS; MALE;

EID: 84892752342     PISSN: 15331458     EISSN: 15390667     Source Type: Journal    
DOI: 10.1097/NAN.0000000000000009     Document Type: Article

References (29)

1. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94 (5 suppl 1): S1-S63. (Pubitemid 40712788)
2. Robak T, Salama A, Kovaleva L, et al. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14 (4): 227-236.
3. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med. 1988;319 (14): 902-907.
4. Sakata K, Hamaoka K, Ozawa S, et al. A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease. Eur J Pediatr. 2007;166 (6): 565-571. (Pubitemid 46643691)
5. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev. 2010;6: CD002063.
6. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7 (2): 136-144.
7. Leger JM, Vargas S, Lievens I. Efficacy of intravenous immunoglobulin in multifocal motor neuropathy. Ann NY Acad Sci. 2007;1110: 248-255. (Pubitemid 350043013)
8. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008 (1): CD002277.
9. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30 (5): 734-745.
10. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26 (3): 265-273. (Pubitemid 43901655)
11. Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103 (9): 856-863.
12. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol. 2009;16 (5): 631-638.
13. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2008;37 (3): 406-409. (Pubitemid 351304803)
14. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11 (6): 532-538.
15. Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15 (6): 238-245.
16. Hizentra (Immune Globulin Subcutaneous [Human], 20% Liquid). Kankakee, IL: CSL Behring, LLC; 2011.
17. Gammagard liquid (Immune Globulin Infusion [Human] 10%). Westlake Village, CA: Baxter Healthcare Corporation; 2011.
18. Gamunex-C (Immune Globulin Injection [Human] 10% caprylate/chromatography purified). Research Triangle Park, NC: Grifols Therapeutics, Inc.; 2010.
19. Wasserman RL. Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations. Patient Prefer Adherence. 2008;2: 163-166.
20. Murphy E, Burton J, Riley P. Nursing approaches to a novel subcutaneous immunoglobulin therapy: a look at 4 patients during transition from IVIg to SCIg. Infusion. 2007;13 (4 suppl): 1-8.
21. National Institutes of Health. Giving a subcutaneous injection. Available at http://www.cc.nih.gov/ccc/patient-education/pepubs/subq.pdf. Accessed October 12, 2012.
22. Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther. 2004;26 (10): 1663-1678. (Pubitemid 39643027)
23. Shim WS, Oh U. Histamine-induced itch and its relationship with pain. Mol Pain. 2008;4: 29.
24. Juul KA, Bengtsson H, Eyving B, et al. Influence of hypodermic needle dimensions on subcutaneous injection delivery-a pig study of injection deposition evaluated by CT scanning, histology, and backflow. Skin Res Technol. 2012;18 (4): 447-455.
25. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;11 (3): 195-201.
26. Egekvist H, Bjerring P, Arendt-Nielsen L. Pain and mechanical injury of human skin following needle insertions. Eur J Pain. 1999;3 (1): 41-49. (Pubitemid 29166621)
27. Parker RK, White PF. A microscopic analysis of cut-bevel versus pencil-point spinal needles. Anesth Analg. 1997;85 (5): 1101-1104. (Pubitemid 27471531)
28. Kinast P. Quality testing of medical needles-laboratory and practice. Med Device Technol. 1992;3 (6): 46-49.
29. Sealfon A, Baker PM. Impact of needle sets on delivery of subcutaneous IgG (SCIG) in patients reporting infusion site reactions. Presented at National Home Infusion Association Annual Conference; Phoenix, AZ; April 23-26, 2012.